Facebook
Twitter
LinkedIn
ForwardThe Changing Landscape of Lung Cancer Biomarkers
The session will provide updated information about former and novel regulatory approvals requiring the use of biomarkers for patient selection to optimal anti-cancer treatments. The focus will be on how to navigate and prioritize biomarkers, optimal use of specimens, scientific rationale and future directions in the field.
It is imperative that therapeutic radiologists, medical oncologists, pathologists and other health professionals have a comprehensive understanding of how to optimally select patients for specific treatment modalities; and how to execute state-of the art biomarker testing using both tumor and non-tumor specimens. This also includes assessment of biomarkers for early diagnosis/screening and treating patients with resectable disease using neoadjuvant treatments.
The session will discuss the current landscape and future directions of the use of biomarkers to select lung cancer patients for optimal treatments. The topics will include detailed discussion about current molecular biomarkers for standard treatments (e.g., chemotherapy, radiation, targeted therapies, immunotherapy and antibody-drug conjugates) as well as future directions in this field. The topics will also discuss biomarkers for early cancer detection, early stage disease and the role of advanced computational methods such as machine learning and artificial intelligence.
Target Audience
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Understand the current landscape of clinical predictive biomarkers to select patients with thoracic malignancies for optimal treatment.
- Understand the biological principles underlying the use of clinical biomarkers for patient selection and stratification.
- Prioritize the use of biospecimens for biomarker testing for patients with thoracic malignancies in both advanced and early stage disease.
Moderator:
- Kurt Schalper, MD
Speakers:
- Kurt Schalper, MD
- Triparna Sen, PhD
- Sanja Dacic, MD, PhD
- Anant Madabhushi, PhD
Faculty:
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.
Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.